Expand CNTB Menu
CNTB MENU

CNTB Latest Press Releases

-- April 23, 2026 --

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis Globe Newswire 9:00 AM

-- March 31, 2026 --

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- March 30, 2026 --

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study Globe Newswire 7:06 AM
Connect Biopharma Announces $20.2 Million Private Placement Financing Globe Newswire 7:02 AM
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD Globe Newswire 7:00 AM

-- March 10, 2026 --

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting Globe Newswire 9:00 AM

-- March 3, 2026 --

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference Globe Newswire 9:00 AM

-- February 19, 2026 --

Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Globe Newswire 9:00 AM

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

-- January 12, 2026 --

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes